Clinica Chimica Acta最新文献

{"title":"An interference in bilirubin detection: Pulmonary marginal zone lymphoma presenting monoclonal cryoglobulin.","authors":"Yi Li, Liangqiong Zhou, Kangyi Wang, Xiaoge Luo, Liqun Zhang, Kaiyong Cai","doi":"10.1016/j.cca.2024.120066","DOIUrl":"10.1016/j.cca.2024.120066","url":null,"abstract":"<p><p>Marginal zone lymphoma (MZL) of the lung is an indolent B-cell lymphoma. The peripheral blood of most patients with pulmonary MZL contains low or undetectable monoclonal immunoglobulin (M protein) levels. In this case, the clinical laboratory discovered that the pulmonary MZL patient not only associated with high concentration of monoclonal IgG-type protein but also exhibited obvious gel formation characteristics that interfered with clinical biochemistry tests. Thus, the role of M protein in total bilirubin determination was examined in this study. Total bilirubin detection curve difference comparison between monoclonal IgG protein and polyclonal immunoglobulin, interference experiments, and dilution elimination experiments were conducted. These experiments revealed not only a positive correlation between M protein interference in bilirubin detection with its concentration, but also M protein-specific interference distinct from polyclonal immunoglobulin. We employed the R and EmpowerStat statistical systems to evaluate the correlation between serum monoclonal protein and total bilirubin absorbance curve data. Multivariate analysis revealed a nonlinear correlation between with globulin (GLB) and square root transformed curve optical density (OD) data. The receiver operating characteristic (ROC) curve analysis indicated an area under the curve (AUC) of 0.852 for the GLB ≥ 31.9 g/L subgroup using combined curve indicators. Our findings can enhance clinical M protein screening and scientific assessment of the populations requiring serum protein electrophoresis testing, thereby reducing the rate of missed diagnoses in the M protein population.</p>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":" ","pages":"120066"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanoparticle biosensors for cardiovascular disease detection.","authors":"Mohamed J Saadh, Faris Anad Muhammad, Rafid Jihad Albadr, Ashok Kumar Bishoyi, Suhas Ballal, Lakshay Bareja, K Satyam Naidu, Jasur Rizaev, Waam Mohammed Taher, Mariem Alwan, Mahmood Jasem Jawad, Ali M Ali Al-Nuaimi","doi":"10.1016/j.cca.2024.120094","DOIUrl":"10.1016/j.cca.2024.120094","url":null,"abstract":"<p><p>Early detection and management of cardiovascular diseases (CVDs) are crucial for patient survival and long-term health. CVD biomarkers such as cardiac Troponin-I (cTnI), N-terminal pro-brain natriuretic peptide (NT-proBNP), creatine kinase MB (CK-MB), Galectin-3 (Gal-3), etc are released into the circulation following heart muscle injury, ie, acute myocardial infarction (AMI). Biosensor technology including the use of nanoparticles can be designed to target specific biomarkers associated with CVD, enabling early detection and more rapid intervention to decrease morbidity and mortality. To date, with the combination of developed nanoparticles, several optical and electrochemical-based biosensors have successfully been used detection of CVD biomarkers. Nanomaterials, when introduced as the modifiers of sensor surfaces like electrodes and gold chips, can result in the more comprehensive and more effective immobilization of capture molecules, ie, antibodies, aptamers and other ligands, due to their large surface area. In recent years, inorganic nanoparticles have regularly been used in the production of biosensors mostly due to their excellent response intensification, adaptable functionalization chemistry, shape control, good biocompatibility, and great stability. In this review, we discuss the application of different kinds of nanoparticles for the sensitive and specific detection of CVD biomarkers.</p>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":" ","pages":"120094"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142834163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determination of new biomarkers for diagnosis of pyridoxine dependent epilepsy in human plasma and urine by liquid chromatography-mass spectrometry.","authors":"Roberta Damiano, Maria Della Bona, Elena Procopio, Serena Gasperini, Renzo Guerrini, Alessandra Bettiol, Giancarlo la Marca","doi":"10.1016/j.cca.2024.120111","DOIUrl":"10.1016/j.cca.2024.120111","url":null,"abstract":"<p><strong>Background: </strong>Pyridoxine-dependent epilepsy (PDE) is a rare inborn error of lysine metabolism. To date, diagnosis of PDE relies on the quantification of α-AminoAdipic SemiAldehyde (α- AASA), Piperideine-6-Carboxylate (P6C) and Pipecolic acid (PA) in urine or plasma from patients with overt symptoms. However, these biomarkers are not specific, and their biochemical analysis is challenged by their instability and technical limitations. We set-up and validated a method for the quantification of two new biomarkers of PDE (2S,6S- and 2S,6R-oxopropylpiperidine-2-carboxylic acid, 2-OPP, and 6-oxopiperidine2-carboxylic acid, 6-oxoPIP) on human urine and plasma by LC-MS/MS, to overcome the diagnostic and technical challenges of old biomarkers.</p><p><strong>Methods: </strong>We analysed urine and plasma samples by LC-MS/MS, and validated the method in both biological matrices.</p><p><strong>Results: </strong>We performed the biomarkers extraction from a 10 µL aliquot of urine or plasma in around 15 min using water 100 % for urine, and a solution of water/methanol 50 % for plasma, respectively. The analytical method was validated and gave good linearity (r² > 0.999) in the range 0-15 µmol/L for 2-OPP and 0-25 µmol/L for 6-oxoPIP. In both matrices, the biomarkers were stable at different storage temperatures tested.</p><p><strong>Conclusions: </strong>We set-up and validated a reliable method and confirmed its clinical applicability on real samples from PDE patients. This method could be used as routine test for the diagnosis and monitoring of PDE.</p>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"567 ","pages":"120111"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MiR-363: A potential biomarker of kidney diseases.","authors":"Yiqi Huang, Jiazhen Zhou, Yaotang Deng, Guoliang Li, Shuirong He, Hecheng Li, Lili Liu","doi":"10.1016/j.cca.2024.120049","DOIUrl":"10.1016/j.cca.2024.120049","url":null,"abstract":"<p><p>MicroRNAs (miRNAs), a class of endogenous small RNAs with lengths of approximately 19-24 nucleotides, play important regulatory roles in cells. In recent years, miR-363 has emerged as a prominent member of the miR-92a family, participating in various biological functions, including cellular proliferation, cycle, migration, and apoptosis. In particular, miR-363 plays a critical role in acute kidney injury, renal fibrosis, and diabetic nephropathy and can serve as a biomarker for the diagnosis of renal cell carcinoma. Ongoing research is exploring its potential as a biomarker of other kidney diseases. This review focuses on the role of miR-363 in kidney diseases, elucidating its regulatory mechanisms and exploring its possible value as a biomarker of kidney diseases.</p>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":" ","pages":"120049"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142779473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in laboratory diagnosis of Sjogren's disease in children.","authors":"Yuemeng Li, Wenxiu He, Yu Zhou, Haotian Chen, Pengyue You, Danni Mu, Yichen Ma, Yumeng Gao, Kaiduo Xu, Haitao Dong, Xinqi Cheng","doi":"10.1016/j.cca.2024.120095","DOIUrl":"10.1016/j.cca.2024.120095","url":null,"abstract":"<p><p>Sjogren's disease (SjD) in children is a rare chronic autoimmune disease not fully recognized due to clinical manifestations different from adults. As such, new objective indicators are needed to supplement existing markers and assist in diagnosis. This review summarizes pathogenesis of SjD in children, current diagnostic criteria and research progress in laboratory diagnosis including serologic testing, saliva and tear analysis, histopathological examination as well as emerging markers of interest.</p>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":" ","pages":"120095"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142833800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biosensors for the detection of celiac disease.","authors":"Asma Vafadar, Parisa Vosough, Shayan Khalili Alashti, Saeed Taghizadeh, Amir Savardashtaki","doi":"10.1016/j.cca.2024.120092","DOIUrl":"10.1016/j.cca.2024.120092","url":null,"abstract":"<p><p>Celiac disease (CeD) is an autoimmune disorder triggered by sensitivity to gluten, a protein complex found in wheat, barley, and rye. Gliadins, a component of gluten, are proteins that trigger an immune response in individuals with CeD, primarily affecting the small intestine's inner lining. Despite a 1-1.5% prevalence, only 24% of cases are diagnosed due to non-specific symptoms. Screening is advised for high-risk groups, including first-degree relatives and type 1 diabetes patients. The accurate diagnosis of this condition and the assessment of the patient's response to the current treatment - a lifelong gluten-free diet - necessitate using dependable, swift, sensitive, specific, uncomplicated, and affordable analytical methods. Detecting CeD biomarkers in whole blood, serum, or plasma provides a non-invasive approach that serves as an ideal initial diagnostic step. Biosensors offer a novel and alternative way for CeD detection, began emerging in 2007, and hold promise for clinical and point-of-care applications. This review explores the use of biomarker-based diagnostic approaches for CeD, with a focus on biosensors. It delves into the progress of biosensors for CeD diagnosis, identifying trends and challenges in this evolving field. Key biomarkers are highlighted, offering insights into the evolving landscape of biosensors in CeD detection.</p>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":" ","pages":"120092"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142834045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proteomics of neuropsychiatric disorders.","authors":"Afeng Liu, Lina Sun, Wenshu Meng","doi":"10.1016/j.cca.2024.120093","DOIUrl":"10.1016/j.cca.2024.120093","url":null,"abstract":"<p><p>The pathogenesis of neuropsychiatric disorders (NDs) remains largely unclear, hence there is a lack of objective and reliable biomarkers. Proteomics, as a powerful tool for disease biomarkers research, has been largely ignored in the field of NDs. This review summarizes recent research on the application of mass spectrometry-based proteomics in NDs. Proteins associated with NDs have been identified in various sample sources, including blood, urine, saliva, tear, cerebrospinal fluid, and brain tissue. These studies have preliminarily demonstrated the potential of proteomics in NDs and require comprehensive validation in multi-center, large-scale clinical cohorts. We also discuss the challenges and prospects of proteomics in the research of early diagnostic biomarkers for NDs. These findings may provide a foundation for developing proteomic-based diagnostics and advancing precision medicine in NDs.</p>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":" ","pages":"120093"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142834168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Soluble oncostatin M receptor (sOSMR): A potential biomarker in systemic sclerosis diagnosis","authors":"Eudes Gustavo Constantino Cunha ,&nbsp;Anderson Rodrigues de Almeida ,&nbsp;Andréa Tavares Dantas ,&nbsp;Maria Eduarda de Oliveira Gonçalves ,&nbsp;Michelly Cristiny Pereira ,&nbsp;Rafaela Silva Guimarães Gonçalves ,&nbsp;Angela Luzia Branco Pinto Duarte ,&nbsp;Moacyr Jesus Barreto de Melo Rêgo ,&nbsp;Maira Galdino da Rocha Pitta","doi":"10.1016/j.cca.2025.120177","DOIUrl":"10.1016/j.cca.2025.120177","url":null,"abstract":"<div><h3>Background</h3><div>Systemic sclerosis (SSc) is a complex disease whose diagnosis is based on clinical manifestations, serological testing for autoantibodies, and nailfold capillaroscopy. Although some proteins have been proposed as biomarkers, the diagnosis of SSc remains a challenge for clinicians. The soluble oncostatin M receptor (sOSMR) is a potential biomarker for the diagnosis of SSc, as it appears to act as an antagonist of oncostatin M (OSM)-mediated signaling, which is involved in biological and inflammatory processes, including tissue injury and fibrosis. Therefore, this study aimed to evaluate the diagnostic performance of sOSMR in systemic sclerosis.</div></div><div><h3>Methodology</h3><div>Serum samples were collected from 105 patients with SSc, 50 with rheumatoid arthritis (RA), 64 with systemic lupus erythematosus (SLE), and 130 healthy controls (HC). The sOSMR levels were measured using an ELISA kit, and a receiver operating characteristic (ROC) curve was used to analyze the biomarker’s potential for diagnosing SSc.</div></div><div><h3>Results</h3><div>sOSMR levels are significantly elevated in the serum of patients with SSc when compared to patients with RA and SLE, as well as healthy controls (p &lt; 0.0001 for all comparisons). The area under the curve (AUC) of ROC curve analysis revealed the ability of sOSMR serum levels to distinguish patients with SSc from those with RA (0.901 [95 % CI 0.842–0.943]; p &lt; 0.0001), with a sensitivity of 89.52 % and specificity of 78.00 %, and from patients with SLE (0.897 [95 % CI 0.841–0.938]; p &lt; 0.0001), with a sensitivity of 81.90 % and specificity of 89.06 %, as well as from healthy controls (0.876 [95 % CI 0.827 – 0.916]; p &lt; 0.0001), with a sensitivity of 82.86 % and specificity of 81.54 %. When comparing patients with SSc to patients with other diseases (RA and SLE combined), an AUC of 0.898 ([95 % CI 0.851–0.935]; p &lt; 0.0001) was found, with a sensitivity of 82.86 % and specificity of 85.09 %.</div></div><div><h3>Conclusion</h3><div>Serum sOSMR levels are elevated in patients with SSc and have shown a good ability to distinguish between SSc patients, patients with other autoimmune rheumatologic diseases (RA and SLE), and healthy controls. Thus, sOSMR is a promising marker for diagnosing SSc.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"569 ","pages":"Article 120177"},"PeriodicalIF":3.2,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143078768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Irisin in thyroid diseases\" [Clin. Chim. Acta 564 (2025) 119929].","authors":"Qi Chen, Jing Wang, Kang Li, Jun-Qin Luan, Jing-Mei Li, Ya-Ting Wang","doi":"10.1016/j.cca.2024.120034","DOIUrl":"10.1016/j.cca.2024.120034","url":null,"abstract":"","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":" ","pages":"120034"},"PeriodicalIF":3.2,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142643877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanomaterial sensors for enhanced detection of serotonin","authors":"Irfan Ahmad ,&nbsp;Fadhel F. Sead ,&nbsp;Prakash Kanjariya ,&nbsp;Anjan Kumar ,&nbsp;Asha Rajivm ,&nbsp;Aman Shankhyan ,&nbsp;Sachin Jaidka ,&nbsp;Harish Kumar ,&nbsp;Zafar Aminov","doi":"10.1016/j.cca.2025.120160","DOIUrl":"10.1016/j.cca.2025.120160","url":null,"abstract":"<div><div>The detection of serotonin (5-HT), a critical neurotransmitter, has garnered significant attention in biosensor research because of its pivotal role in neurological and physiological processes. This narrative review highlights advancements in nanomaterial-based sensors designed to increase the sensitivity, specificity, and functionality of serotonin detection. Carbon-based nanomaterials, including carbon nanotubes (CNTs), graphene derivatives, and carbon nanofibers (CNFs), have demonstrated remarkable potential owing to their large surface area, superior electrical conductivity, and biocompatibility. These materials enable rapid electron transfer and selective serotonin adsorption, making them integral to electrochemical and wearable sensor technologies. Emerging technologies, including field-effect transistors (FETs), magnetoelastic biosensors, and molecularly imprinted polymers (MIPs), have demonstrated ultralow detection limits and real-time monitoring capabilities, suggesting promising applications for clinical diagnostics and personalized healthcare. Metal-based sensors, which utilize nanoparticles of gold, silver, and other metals, have also shown exceptional performance in serotonin detection through enhanced electrocatalysis and optical properties. This review underscores the transformative potential of nanomaterial-based sensors in serotonin detection, emphasizing their role in advancing neuroscience research, disease diagnostics, and therapeutic monitoring.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"569 ","pages":"Article 120160"},"PeriodicalIF":3.2,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143074092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}